Literature DB >> 12058349

Genome screen to identify susceptibility genes for Parkinson disease in a sample without parkin mutations.

Nathan Pankratz1, William C Nichols, Sean K Uniacke, Cheryl Halter, Alice Rudolph, Cliff Shults, P Michael Conneally, Tatiana Foroud.   

Abstract

Parkinson disease (PD) is a common neurodegenerative disorder characterized by bradykinesia, resting tremor, muscular rigidity, and postural instability, as well as by a clinically significant response to treatment with levodopa. Mutations in the alpha-synuclein gene have been found to result in autosomal dominant PD, and mutations in the parkin gene produce autosomal recessive juvenile-onset PD. We have studied 203 sibling pairs with PD who were evaluated by a rigorous neurological assessment based on (a) inclusion criteria consisting of clinical features highly associated with autopsy-confirmed PD and (b) exclusion criteria highly associated with other, non-PD pathological diagnoses. Families with positive LOD scores for a marker in an intron of the parkin gene were prioritized for parkin-gene testing, and mutations in the parkin gene were identified in 22 families. To reduce genetic heterogeneity, these families were not included in subsequent genome-screen analysis. Thus, a total of 160 multiplex families without evidence of a parkin mutation were used in multipoint nonparametric linkage analysis to identify PD-susceptibility genes. Two models of PD affection status were considered: model I included only those individuals with a more stringent diagnosis of verified PD (96 sibling pairs from 90 families), whereas model II included all examined individuals as affected, regardless of their final diagnostic classification (170 sibling pairs from 160 families). Under model I, the highest LOD scores were observed on chromosome X (LOD score 2.1) and on chromosome 2 (LOD score 1.9). Analyses performed with all available sibling pairs (model II) found even greater evidence of linkage to chromosome X (LOD score 2.7) and to chromosome 2 (LOD score 2.5). Evidence of linkage was also found to chromosomes 4, 5, and 13 (LOD scores >1.5). Our findings are consistent with those of other linkage studies that have reported linkage to chromosomes 5 and X.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12058349      PMCID: PMC384969          DOI: 10.1086/341282

Source DB:  PubMed          Journal:  Am J Hum Genet        ISSN: 0002-9297            Impact factor:   11.025


  57 in total

1.  Refined linkage disequilibrium and physical mapping of the gene locus for X-linked dystonia-parkinsonism (DYT3).

Authors:  A H Németh; D Nolte; E Dunne; S Niemann; M Kostrzewa; U Peters; E Fraser; E Bochukova; R Butler; J Brown; R D Cox; E R Levy; H H Ropers; A P Monaco; U Müller
Journal:  Genomics       Date:  1999-09-15       Impact factor: 5.736

2.  Multiple ligand interaction of alpha-synuclein produced various forms of protein aggregates in the presence of Abeta25-35, copper, and eosin.

Authors:  Y S Kim; D Lee; E K Lee; J Y Sung; K C Chung; J Kim; S R Paik
Journal:  Brain Res       Date:  2001-07-20       Impact factor: 3.252

3.  A genetic study of Parkinson's disease.

Authors:  G De Michele; A Filla; R Marconi; G Volpe; A D'Alessio; R Scala; G Ambrosio; G Campanella
Journal:  J Neural Transm Suppl       Date:  1995

4.  Absence of mutations in the coding region of the alpha-synuclein gene in pathologically proven Parkinson's disease.

Authors:  P Chan; X Jiang; L S Forno; D A Di Monte; C M Tanner; J W Langston
Journal:  Neurology       Date:  1998-04       Impact factor: 9.910

5.  "Familial Parkinson's disease"--a case-control study of families.

Authors:  R J Uitti; H Shinotoh; M Hayward; M Schulzer; E Mak; D B Calne
Journal:  Can J Neurol Sci       Date:  1997-05       Impact factor: 2.104

6.  A genetic study of Wilson's disease: evidence for heterogeneity.

Authors:  D W Cox; F C Fraser; A Sass-Kortsak
Journal:  Am J Hum Genet       Date:  1972-11       Impact factor: 11.025

7.  Park7, a novel locus for autosomal recessive early-onset parkinsonism, on chromosome 1p36.

Authors:  C M van Duijn; M C Dekker; V Bonifati; R J Galjaard; J J Houwing-Duistermaat; P J Snijders; L Testers; G J Breedveld; M Horstink; L A Sandkuijl; J C van Swieten; B A Oostra; P Heutink
Journal:  Am J Hum Genet       Date:  2001-07-02       Impact factor: 11.025

8.  Accuracy of clinical diagnosis of idiopathic Parkinson's disease: a clinico-pathological study of 100 cases.

Authors:  A J Hughes; S E Daniel; L Kilford; A J Lees
Journal:  J Neurol Neurosurg Psychiatry       Date:  1992-03       Impact factor: 10.154

9.  alpha-Synuclein gene and Parkinson's disease. The French Parkinson's Disease Study Group.

Authors: 
Journal:  Science       Date:  1998-02-20       Impact factor: 47.728

10.  [Multifactorial etiology of idiopathic Parkinson disease. A case-control study].

Authors:  P Vieregge; H J Friedrich; A Röhl; G Ulm; I Heberlein
Journal:  Nervenarzt       Date:  1994-06       Impact factor: 1.214

View more
  60 in total

1.  Gender differences in the risk of familial parkinsonism: beyond LRRK2?

Authors:  R Saunders-Pullman; K Stanley; M San Luciano; M J Barrett; V Shanker; D Raymond; L J Ozelius; S B Bressman
Journal:  Neurosci Lett       Date:  2011-04-12       Impact factor: 3.046

2.  The PARK8 locus in autosomal dominant parkinsonism: confirmation of linkage and further delineation of the disease-containing interval.

Authors:  Alexander Zimprich; Bertram Müller-Myhsok; Matthew Farrer; Petra Leitner; Manu Sharma; Mary Hulihan; Paul Lockhart; Audrey Strongosky; Jennifer Kachergus; Donald B Calne; Jon Stoessl; Ryan J Uitti; Ronald F Pfeiffer; Claudia Trenkwalder; Nikolaus Homann; Erwin Ott; Karoline Wenzel; Friedrich Asmus; John Hardy; Zbigniew Wszolek; Thomas Gasser
Journal:  Am J Hum Genet       Date:  2003-12-19       Impact factor: 11.025

3.  Risk factors for Parkinson's disease may differ in men and women: an exploratory study.

Authors:  Rodolfo Savica; Brandon R Grossardt; James H Bower; J Eric Ahlskog; Walter A Rocca
Journal:  Horm Behav       Date:  2012-06-08       Impact factor: 3.587

Review 4.  Parkinson's disease in women: a call for improved clinical studies and for comparative effectiveness research.

Authors:  J M Pavon; H E Whitson; M S Okun
Journal:  Maturitas       Date:  2010-02-01       Impact factor: 4.342

5.  Gender and the Parkinson's disease phenotype.

Authors:  Yasuhiko Baba; John D Putzke; Nathaniel R Whaley; Zbigniew K Wszolek; Ryan J Uitti
Journal:  J Neurol       Date:  2005-09-12       Impact factor: 4.849

6.  Mutation analysis of the seven in absentia homolog 1 (SIAH1) gene in Parkinson's disease.

Authors:  T Franck; R Krueger; D Woitalla; T Müller; S Engelender; O Riess
Journal:  J Neural Transm (Vienna)       Date:  2006-06-06       Impact factor: 3.575

7.  Genome-wide scan linkage analysis for Parkinson's disease: the European genetic study of Parkinson's disease.

Authors:  M Martinez; A Brice; J R Vaughan; A Zimprich; M M B Breteler; G Meco; A Filla; M J Farrer; C Bétard; J Hardy; G De Michele; V Bonifati; B Oostra; T Gasser; N W Wood; A Dürr
Journal:  J Med Genet       Date:  2004-12       Impact factor: 6.318

8.  Verification of self-report of zygosity determined via DNA testing in a subset of the NAS-NRC twin registry 40 years later.

Authors:  Terry Reed; Brenda L Plassman; Caroline M Tanner; Danielle M Dick; Shannon A Rinehart; William C Nichols
Journal:  Twin Res Hum Genet       Date:  2005-08       Impact factor: 1.587

9.  Olfactory dysfunction in LRRK2 G2019S mutation carriers.

Authors:  R Saunders-Pullman; K Stanley; C Wang; M San Luciano; V Shanker; A Hunt; L Severt; D Raymond; L J Ozelius; R B Lipton; S B Bressman
Journal:  Neurology       Date:  2011-07-13       Impact factor: 9.910

10.  ParkScreen: a low-cost rapid linkage marker panel for Parkinson's disease.

Authors:  Alessandro De Grandi; Claudia Béu Volpato; Elisa Bedin; Cristian Pattaro; Fabio Marroni; Irene Pichler; Andrew Antony Hicks; Giorgio Casari; Peter Paul Pramstaller
Journal:  J Mol Neurosci       Date:  2009-03-25       Impact factor: 3.444

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.